drugset / Trial / NCT00185302
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
Primary objective: To evaluate the efficacy of two different dosing schedules of MS-275 in subjects with metastatic melanoma Secondary objectives: To evaluate the safety and to assess the pharmacokinetic profile of MS-275 in subjects with metastatic melanoma
Timeline
- Start
- 2004-12
- Primary completion
- 2006-07
- Completion
- 2006-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entinostat | Small molecule | 3 mg | Oral |
| Subject | Entinostat | Small molecule | 7 mg | Oral |